title: Management of acute and fulminant hepatitis A.
abstract: Symptomatic viral hepatitis A usually only requires supportive therapy and the majority of cases are managed in the community. The prodromal symptoms of nausea, anorexia and lethargy tend to improve with the onset of clinical jaundice. Fulminant hepatic failure is said to be an uncommon complication, occurring in only 0.14-0.35% of hospitalized cases. However, an increasing incidence has been documented in some northern European countries where up to 20% of cases of fulminant viral hepatitis is due to hepatitis A. This trend parallels the increasingly delayed exposure to hepatitis A and the increased severity of the illness when contracted in later life. The risk of developing fulminant hepatic failure is best monitored using coagulation factor assays, with the prothrombin time and factor V levels being the most favoured. The diagnosis is established with the onset of encephalopathy. Patients progressing to grade 4 encephalopathy have a reasonably good prognosis compared to other aetiologies and survival rates of up to 67% have been obtained with medical management, despite the co-existence of such complications as cerebral oedema, renal and respiratory failure and the metabolic sequelae of acute liver failure. Nevertheless, some patients require emergency liver transplantation and 10 such patients have been reported to date. Transplantation is especially required in older patients (> 40 years) and those who are jaundiced for > 7 days before the onset of encephalopathy. The serum bilirubin and the prothrombin time complement these parameters in the decision making process.
authors: Institute of Liver Studies, King's College Hospital, Denmark Hill, London, UK.
authors: J
authors: J
authors: O'Grady
mesh_terms: D000208:Acute Disease; D058186:Acute Kidney Injury / Q000209:etiology / Q000628:therapy; D000328:Adult; D001929:Brain Edema / Q000209:etiology / Q000628:therapy; D003131:Combined Modality Therapy; D006501:Hepatic Encephalopathy / Q000209:etiology / Q000628:therapy*; D006506:Hepatitis A / Q000150:complications / Q000628:therapy*; D006801:Humans; D007003:Hypoglycemia / Q000209:etiology / Q000628:therapy; D007239:Infections / Q000209:etiology / Q000628:therapy; D007565:Jaundice; D016031:Liver Transplantation; D012307:Risk Factors; D012769:Shock / Q000209:etiology / Q000628:therapy